⚠ Notice: SCAC Restructuring

The Stanford Securities Class Action Clearinghouse (SCAC) is currently under construction and is temporarily unavailable as it undergoes updates and improvements. The Clearinghouse is expected to return as part of the Stanford Rock Center for Corporate Governance in Winter 2026.

During this period, updates and new filings will not be available.

For urgent inquiries, please contact rockprograms@law.stanford.edu.

Processing your request


please wait...
Stanford Law School Securities Class Action Clearinghouse a Collaboration with Cornerstone Research

Case Page

 

Spectrum Pharmaceuticals, Inc.

Case Summary

Spectrum Pharmaceuticals, Inc. Securities Litigation

Case Summary

Case Status:    DISMISSED  
—On or around 12/11/2015 (Notice of voluntarily dismissal)
Current/Last Presiding Judge:  
Hon. James C. Mahan

Filing Date: November 03, 2015

Spectrum Pharmaceuticals, Inc. ("Spectrum") is an American biopharmaceutical company focused on developing oncology therapies.

According to a law firm press release, the Complaint alleges on October 23, 2015, Spectrum announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in response to its New Drug Application seeking clearance for Evomela, indicating that the FDA cannot approve the application in its present form. When the truth was revealed, shares dropped causing investors harm.

This case was voluntarily dismissed on December 11, 2015.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.